AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

About this update from Amgen Inc.

[{"type":"text","content":"THOUSAND OAKS, Calif., Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.","length":190,"tagName":"p"},{"type":"text","content":""Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth," said Robert A. Bradway, chairman and chief executive officer.","length":339,"tagName":"p","attribs":{}},{"type":"text","content":"Key results include:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"For the fourth quarter, total revenues increased 9% to $9.9 billion in comparison to the fourth quarter of 2024.","length":112,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Product sales grew 7%, driven by 10% volume growth, partially offset by 4% lower net selling price.","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":99,"olType":false}]},{"val":[{"type":"text","content":"For the full year, total revenues increased 10% to $36.8 billion in comparison to the full year of 2024.","length":104,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Product sales grew 10%, driven by 13% volume growth, partially offset by 3% lower net selling price.","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Eighteen products achieved record sales for the full year.","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourteen products exceeded one billion dollars in annual sales.","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Thirteen products delivered at least double-digit sales growth for the full year.","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":302,"olType":false}]},{"val":[{"type":"text","content":"GAAP earnings per share (EPS) increased 111% from $1.16 to $2.45 for the fourth quarter, driven by higher revenues and lower net unrealized losses on equity investments, partially offset by higher operating expenses. For the full year, GAAP EPS increased 88% from $7.56 to $14.23, driven by higher revenues and net unrealized gains on our BeOne Medicines Lt...

More updates from Amgen Inc.